Swiss biopharma developing and selling small-molecule drugs, including its insomnia treatment Quviviq (daridorexant).
Swiss biopharma developing and selling small-molecule drugs, including its insomnia treatment Quviviq (daridorexant).
Formed in 2017 when Actelion, bought by Johnson & Johnson, spun its drug-discovery arm into a new company led by its founders. Earns from its own launches of Quviviq in the US and Europe plus licence fees and milestones from partners, such as Viatris for two late-stage drugs, and has had to restructure its debt.
In one line: A smaller, cash-strapped Swiss Vertex Pharmaceuticals.
Moat: narrow (IP / patents). Patent-protected molecules, but reliant on continued launches amid a heavy debt load.
Headquarters: Allschwil, Switzerland · Founded: 2017 · Employees: 487
Size Idorsia (IDIA.SW) is a Switzerland Health Care company (Pharmaceuticals: Major) with a market value of $1.22B, the 113th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 3.84 on 18 Nov 2026.
Performance Over six months the shares fell 9.1%, against -22.2% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue fell 5.3% over the last twelve months (peer median +7.6%); the operating margin is -69.7% (peer median -2.1%).
Valuation It trades at 10.4× enterprise value to sales against a peer median of 8.6× (8th most expensive of 18).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 220M | CHF 221M | CHF 113M | CHF 152M | CHF 97.1M |
| Revenue growth | — | +96% | -26% | +57% | — |
| Gross profit | CHF 163M | CHF 182M | CHF 58.7M | CHF 126M | CHF 71.0M |
| EBITDA | -CHF 138M | -CHF 114M | -CHF 326M | -CHF 524M | -CHF 783M |
| Net income | -CHF 284M | -CHF 112M | -CHF 264M | -CHF 298M | -CHF 828M |
| Free cash flow | -CHF 114M | -CHF 169M | -CHF 373M | -CHF 638M | -CHF 876M |
| Capital expenditure | CHF 9.43M | CHF 13.8M | CHF 18.0M | CHF 9.40M | CHF 27.1M |
| Total debt | CHF 1.35B | CHF 1.29B | CHF 1.26B | CHF 1.20B | CHF 1.23B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Idorsia IDIA.SW | $1.22B | -9% | -5% | -70% | 10.4× | n/a |
| Vertex Pharmaceuticals VRTX | $136B | +25% | +11% | 35% | 10.5× | 6.2% |
| Jazz Pharmaceuticals Public JAZZ | $15.9B | +4% | +13% | 25% | 4.0× | -2.8% |
| Roche RO.SW | $381B | +21% | -1% | 31% | 5.7× | 1.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IDIA.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.5% | -5.4% | 7th lowest of 21 |
| 6-month return | -9.1% | -22.2% | 7th highest of 21 |
| Distance from 52-week high | -49.2% | -41.7% | 6th lowest of 21 |
| Revenue growth (TTM) | -5.3% | +7.6% | 6th lowest of 18 |
| Operating margin | -69.7% | -2.1% | 6th lowest of 18 |
| EV / Sales | 10.4× | 8.6× | 8th most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | 10.4× | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 1.8× | 7.0% | -5.3% |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | 818.8× | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 4.7× | n/a | n/a |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | 17.0× | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | 10.4× | 44.1% | -13.2% |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 0.5× | n/a | n/a |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.20B | -29% | +21% | -127% | 13.6× | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 4.8× | 3.4% | +27.9% |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 39.1× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 7.6× | n/a | n/a |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 2.3× | 2.5% | +15.5% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | 8.6× | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | 13.3× | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | 13.2× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 2.0× | -0.4% | -1.3% |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 2.6× | -4.0% | -9.0% |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 12.8× | n/a | n/a |